



US009409856B2

(12) **United States Patent**
Dalton et al.

(10) **Patent No.:** **US 9,409,856 B2**

(45) **Date of Patent:** ***Aug. 9, 2016**

(54) **ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF**

C07C 235/24 (2006.01)

C07C 235/38 (2006.01)

C07C 251/48 (2006.01)

(71) Applicant: **GTx, Inc.**, Memphis, TN (US)

(52) **U.S. Cl.**

CPC *C07C 215/82* (2013.01); *A61K 31/137*

(2013.01); *A61K 31/167* (2013.01); *A61K*

31/4453 (2013.01); *C07C 233/75* (2013.01);

C07C 235/16 (2013.01); *C07C 235/24*

(2013.01); *C07C 235/38* (2013.01); *C07C*

235/56 (2013.01); *C07C 251/48* (2013.01);

C07C 255/58 (2013.01); *C07C 311/21*

(2013.01); *C07C 311/29* (2013.01); *C07D*

211/06 (2013.01); *C07D 221/12* (2013.01);

C07D 295/135 (2013.01); *C07D 295/155*

(2013.01); *C07C 2101/14* (2013.01)

(72) Inventors: **James T. Dalton**, Ann Arbor, MI (US);
Christina Herring, Oakland, TN (US);
Duane D. Miller, Collierville, TN (US);
Seung-Soo Hong, Collierville, TN
(US); **Yali He**, Germantown, TN (US);
Michael L. Mohler, Memphis, TN (US);
Ramesh Narayanan, Cordova, TN (US);
Zhongzhi Wu, Collierville, TN (US)

(73) Assignee: **Gtx, Inc.**, Memphis, TN (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/733,852**

(22) Filed: **Jun. 8, 2015**

(65) **Prior Publication Data**

US 2016/0031797 A1 Feb. 4, 2016

Related U.S. Application Data

(63) Continuation-in-part of application No. 14/063,554, filed on Oct. 1, 2013, now Pat. No. 9,051,267, which is a continuation of application No. 12/710,693, filed on Feb. 23, 2010, now Pat. No. 8,546,451, which is a continuation-in-part of application No. 11/785,251, filed on Apr. 16, 2007, now Pat. No. 8,158,828, which is a continuation-in-part of application No. 11/604,884, filed on Nov. 28, 2006, now abandoned, said application No. 14/043,554 is a continuation-in-part of application No. 13/362,242, filed on Jan. 31, 2012, now abandoned.

(60) Provisional application No. 60/739,898, filed on Nov. 28, 2005, provisional application No. 61/261,669, filed on Nov. 16, 2009, provisional application No. 61/168,983, filed on Apr. 14, 2009, provisional application No. 61/154,707, filed on Feb. 23, 2009.

(51) **Int. Cl.**

C07C 215/82 (2006.01)

C07C 235/56 (2006.01)

C07D 295/135 (2006.01)

C07C 233/75 (2006.01)

A61K 31/137 (2006.01)

A61K 31/167 (2006.01)

A61K 31/4453 (2006.01)

C07D 221/12 (2006.01)

C07D 211/06 (2006.01)

C07D 295/155 (2006.01)

C07C 255/58 (2006.01)

C07C 311/21 (2006.01)

C07C 311/29 (2006.01)

C07C 235/16 (2006.01)

(58) **Field of Classification Search**

CPC .. *C07C 215/82*; *C07C 233/75*; *C07C 233/56*;

C07C 235/38; *C07C 235/16*; *C07C 235/24*;

C07C 235/56; *C07C 251/48*; *C07C 311/29*;

C07C 311/21; *C07C 255/58*; *C07C 2101/14*;

C07D 221/12; *C07D 211/06*; *C07D 295/35*;

C07D 295/155; *A61K 31/4453*; *A61K 31/167*;

A61K 31/137

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,413,339 A 11/1968 Scherrer

3,625,972 A 12/1971 Schulenberg

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1443187 9/2003

DE 269213 1/1914

(Continued)

OTHER PUBLICATIONS

Wei et al, Org. Letters, 2005, 7(15), 3199-3202.*

(Continued)

Primary Examiner — Shailendra Kumar

(74) *Attorney, Agent, or Firm* — Mark S. Cohen; Pearl

Cohen; Zedek Latzer Baratz LLP

(57) **ABSTRACT**

The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBA compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including, inter alia, prevention and treatment of hormone-related diseases, cancers, inflammation, osteoporosis, peripheral vascular disease, reducing circulating lipid levels, and cardiovascular disease.